Finland· FI-REL-REL50273
Fosaprepitant Accord
A aprepitant product containing fosaprepitant dimeglumine, registered in Finland by Accord Healthcare B.V.. The same ATC class is registered in 17 of our 19 countries.
Checked against Fimea (Finland) on
Informational only — not a medical device.
Where it is registered
Aprepitant is registered in 17 of 19 countries.
Countries holding a registration under ATC A04AD12 (aprepitant), each read from that country’s own register.
- This record: Finland, from Fimea (Finland)
- 9 of them publish a price we can compare per daily dose
Aprepitant · ATC A04AD12
17 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Franceprice
- Germany
- Icelandprice
- Ireland
- Japan
- Netherlands
- Norwayprice
- Polandprice
- Sweden
- Switzerlandprice
- United Kingdom
- United Statesprice
Price per daily dose
What a daily dose of aprepitant costs, country by country.
Normalised to the WHO defined daily dose (165 mg), the median price runs from $0.40 in Finland to $157.48 in United States — a ×394 gap.
- Finland: $0.40 per daily dose (median across products in the class)
- Public list prices, converted to USD at the rate date shown
- US figures are pharmacy acquisition cost (CMS NADAC), not retail
Aprepitant · price per daily dose (165 mg)
USD · FX 28 Sept 2026
- US United States$157.48 (acquisition cost)
- CH Switzerland$73.26
- FR France$33.15
- FI Finland$0.40
The record
At a glance
Fimea (Finland)- Active substance
- Fosaprepitant dimeglumine
- Manufacturer
- Accord Healthcare B.V.
- Country
- Finland (FI)
- ATC code
- A04AD12
- ATC class
- Aprepitant
- Defined daily dose
- 165 mg, O
- Reimbursed
- Not published by this register
- Source register
- Fimea (Finland)
- Last checked
- September 27, 2026
Packs & prices · 0
No packs listed by the register for this record.
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
583 interactions on record for aprepitant.
Graded by severity as the source publishes them — 73 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Aprepitant · interactions on record
583 records
- 73 severe
- 380 moderate
- 25 minor
- 104 info
Most severe, free to view
- CisaprideA03FA02severe
- NaloxegolA06AH03severe
- EliglustatA16AX10severe
- LonafarnibA16AX20severe
1 more interaction with mechanism and management, from a commercially licensed source.
Sign in to check- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same medicine, other countries
Aprepitant in 4 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- CzechiaIVEMENDMerck Sharp & Dohme B.V., Haarlem
- BelgiumIvemend 150 mgMerck Sharp & Dohme
- IrelandIvemend 150 mg Powder for solution for infusionMerck Sharp & Dohme BV,
- United StatesEMENDMerck Sharp & Dohme LLC
Authorised across Europe · EMA
The same active substance is authorised in 1 EEA country. Names it is sold under:
- Spain · Fosaprepitant Zentiva
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Fimea (Finland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/b02ca6bd-242e-4732-ba8a-fde58bf3d1d3 GET /v1/drugs/b02ca6bd-242e-4732-ba8a-fde58bf3d1d3?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"ddd": "150",
"form": "infuusiokuiva-aine, liuosta varten",
"route": "Laskimoon",
"ddd_unit": "mg",
"strength": "150 mg",
"atc_label": "aprepitantti",
"ma_number": "34783",
"auth_status": "Myyntilupa myönnetty",
"eu_ma_number": null,
"fimea_rel_id": "REL50273",
"authorised_at": "2018-02-28"
}See everything about aprepitant.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.